RI
PLX icon

RTW Investments’s Protalix BioTherapeutics PLX Stock Holding History

RTW Investments’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-84,385
Closed -$1.55M – 25
2014
Q4 		$1.55M Buy
+84,385
New +$1.81M 0.57% 18

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

RTW Investments's PLX Position: Q1 2015 in Review

RTW Investments sold out of Protalix BioTherapeutics (PLX) in Q1 2015, closing a stake of 84,385 shares — an estimated $1.55M sold.

RTW Investments first reported a position in PLX in Q4 2014 and held it in 1 quarter. The position peaked at $1.55M in Q4 2014. 37 funds tracked by Wall St. Rank hold PLX as of Q1 2015.

  • RTW Investments reported no remaining Protalix BioTherapeutics position as of Q1 2015 after selling out during the quarter.
  • RTW Investments sold 84,385 Protalix BioTherapeutics shares in Q1 2015, an estimated $1.55M.
  • RTW Investments first reported a position in Protalix BioTherapeutics in Q4 2014 and held it in 1 quarter.
  • RTW Investments's Protalix BioTherapeutics position peaked at $1.55M in Q4 2014.
  • 37 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2015.

Based on RTW Investments's 13F filing for Q1 2015, filed 21 May 2015.